We further focused on p-AKT+ samples to determine whether FGF9 is an active ligand of FGFR1 and whether CX3CR1 is required for FGFR1 activation in PTEN-deficient prostate cancer (Figure 9B and Supplemental Table 1). This evidence concerns the gene PTEN and prostate cancer.